SYNformulas presents the scientifically researched potential of its products at Vitafoods
By: SYNformulas GmbH
SYNformulas has made a pioneering achievement in the treatment of the widespread disease Irritable Bowel Syndrome (IBS), which affects approximately 11% of the world's population : In two independent studies, including the world's largest OTC study , the bacterial strain MIMBb75 has been proven to be significantly effective on all symptoms of IBS such as diarrhea, abdominal pain, flatulence and constipation , . So far, the bacterial strain is exclusively used in the product Kijimea® IBS and in its heat-inactivated form in Kijimea® IBS PRO.
"With extended licensing partnerships, we also want to give other potential partners in the food and pharmaceutical sectors the chance to use our innovations,"
Key Facts SYNformulas at Vitafoods Europe
Date: 05th – 07th October 2021
You will be at Vitafoods Europe and would like to arrange an exclusive interview?
Please contact us at email@example.com .
Managing Director David Rietbrock is also available for interviews in advance.
 Canavan, C. et al. (2014). The epidemiology of irritable bowel syndrome. Clinical Epidemiology;
 Comparison only considers studies with probiotic strains
 Guglielmetti, S. et al. (2011). Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life – A double-blind, placebo-controlled study. Aliment. Pharmacol. Ther. 33, 1123–1132.
 Andresen V. et al. (2020): Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001)